Detalhe da pesquisa
1.
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Qual Life Res
; 32(11): 3053-3061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439961
2.
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Int J Neuropsychopharmacol
; 25(4): 269-279, 2022 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022754
3.
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
Am J Geriatr Psychiatry
; 30(5): 541-556, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750057
4.
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Int J Neuropsychopharmacol
; 24(1): 22-31, 2021 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32861217
5.
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
J Clin Psychopharmacol
; 41(5): 516-524, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34412104
6.
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Am J Geriatr Psychiatry
; 28(2): 121-141, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31734084
7.
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Int J Neuropsychopharmacol
; 22(10): 616-630, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31290965
8.
Comments to Drs Taillefer de Laportalière, Jullien, Yrondi, Cestac, and Montastruc.
Psychol Med
; 53(16): 7980-7982, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37609792
9.
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
J Psychopharmacol
; 37(8): 836-844, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36218274
10.
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA.
Neuropsychiatr Dis Treat
; 19: 693-707, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37025256
11.
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
Neuropsychopharmacology
; 48(8): 1225-1233, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173512
12.
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Int J Neuropsychopharmacol
; 15(1): 107-18, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21777507
13.
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Clin Pharmacol Ther
; 109(2): 536-546, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32860422
14.
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
J Affect Disord
; 281: 767-775, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33261932
15.
Comments to Drs. Bahji, Vazquez, and Zarate.
J Affect Disord
; 283: 262-264, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33571795
16.
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
CNS Drugs
; 35(7): 781-794, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34235612
17.
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
Int J Neuropsychopharmacol
; 13(5): 635-47, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19941696
18.
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
J Clin Psychiatry
; 81(3)2020 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32412700
19.
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
J Clin Psychiatry
; 81(3)2020 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32316080
20.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Focus (Am Psychiatr Publ)
; 17(1): 55-65, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32015715